| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/15/2001 | WO2001011023A1 Treatment of inflammatory or malignant disease using dnazymes |
| 02/15/2001 | WO2001010989A1 Fat compositions |
| 02/15/2001 | WO2001010913A1 Potentiation of inclusion complex formation of cyclodextrin derivatives |
| 02/15/2001 | WO2001010912A1 Multiple cytokine-antibody complexes |
| 02/15/2001 | WO2001010902A2 Nucleoc acids and secreted polypeptides encoded thereby |
| 02/15/2001 | WO2001010901A2 Antimicrobial histone h1 compositions, kits, and methods of use thereof |
| 02/15/2001 | WO2001010895A1 Streptogramin derivatives, production thereof and compositions containing the same |
| 02/15/2001 | WO2001010894A2 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 02/15/2001 | WO2001010893A2 Il-16 antagonists |
| 02/15/2001 | WO2001010879A1 Erythromycin a derivatives |
| 02/15/2001 | WO2001010873A1 Novel 2-decarboxy-2-phosphinico prostaglandin f analogs |
| 02/15/2001 | WO2001010870A1 Transition metal complexes of n,n',n'-trialkyl- cis,cis-1,3,5-triaminocyclohexane and related compositions and methods of synthesis and use |
| 02/15/2001 | WO2001010867A1 Vitronectin receptor antagonists useful for the treatment of strokes |
| 02/15/2001 | WO2001010866A1 Interleukin-5 inhibiting 6-azauracil derivatives |
| 02/15/2001 | WO2001010865A1 p38MAP KINASE INHIBITORS |
| 02/15/2001 | WO2001010859A1 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
| 02/15/2001 | WO2001010848A2 Diazocin-dione derivatives and their use s tryptase inhibitors |
| 02/15/2001 | WO2001010847A2 Novel integrin receptor antagonists |
| 02/15/2001 | WO2001010846A2 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system |
| 02/15/2001 | WO2001010842A2 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 02/15/2001 | WO2001010841A2 Fluorene derivatives as integrin inhibitors |
| 02/15/2001 | WO2001010834A2 Antibacterial agents |
| 02/15/2001 | WO2001010833A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 02/15/2001 | WO2001010831A1 Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists |
| 02/15/2001 | WO2001010829A1 Novel vitamin d analogues |
| 02/15/2001 | WO2001010827A1 Arylsulfonamido-substituted hydroxamic acid derivatives |
| 02/15/2001 | WO2001010823A1 Carboxylic acid amides, their production and their use as drugs |
| 02/15/2001 | WO2001010819A1 Nitroxy derivatives of (r) and (s)-carnitine |
| 02/15/2001 | WO2001010816A2 Substituted 2-dialkylaminoalkylbiphenyl derivatives |
| 02/15/2001 | WO2001010813A1 Crystals of the sodium salt of pravastatin |
| 02/15/2001 | WO2001010742A1 Valve with a valve stem wiper |
| 02/15/2001 | WO2001010741A1 Valve with a two-component seal |
| 02/15/2001 | WO2001010468A2 Drug-carrier complexes and methods of use thereof |
| 02/15/2001 | WO2001010465A1 Moxifloxacin formulation containing common salt |
| 02/15/2001 | WO2001010463A1 Pastes with the sustained release of osteogenesis promoter |
| 02/15/2001 | WO2001010455A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
| 02/15/2001 | WO2001010451A1 Remedies for diabetes |
| 02/15/2001 | WO2001010449A1 Method of maintaining vascular integrity using aicar (5-amino-4-imidazole riboside) and related compounds |
| 02/15/2001 | WO2001010448A1 Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids |
| 02/15/2001 | WO2001010447A1 Use of rhamnolipids in wound healing, treatment and prevention of gum disease and periodontal regeneration |
| 02/15/2001 | WO2001010446A2 Formulations for parenteral use of estramustine phosphate and albumin |
| 02/15/2001 | WO2001010445A1 Neuropathy remedies |
| 02/15/2001 | WO2001010444A2 A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate |
| 02/15/2001 | WO2001010443A1 Pharmaceutical formulations in hydroxypropylmethylcellulose capsules |
| 02/15/2001 | WO2001010442A1 Retinal ganglion cell death inhibitors containing dihydropyridine compounds |
| 02/15/2001 | WO2001010441A1 Torsemide polymorphs |
| 02/15/2001 | WO2001010440A1 COMPOSITIONS AND METHODS TO ENHANCE CANCER CHEMOTHERAPY IN p53 DEFECTIVE TUMORS |
| 02/15/2001 | WO2001010439A1 Cyclic amine ccr3 antagonists |
| 02/15/2001 | WO2001010438A1 Anti-inflammatory actions of cytochrome p450 epoxygenase-derived eicosanoids |
| 02/15/2001 | WO2001010437A1 Methods of modulating matrix metalloproteinase activity and uses thereof |
| 02/15/2001 | WO2001010436A1 Medicinal compositions for treating lower uropathy |
| 02/15/2001 | WO2001010435A1 Patch |
| 02/15/2001 | WO2001010434A1 Pharmaceutical compositions containing n-palmitoylethanolamide and use thereof in the veterinary field |
| 02/15/2001 | WO2001010433A1 Neuropathy improvers containing nitrogenous compounds as the active ingredient |
| 02/15/2001 | WO2001010432A1 Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy |
| 02/15/2001 | WO2001010431A2 Headache and colic relief composition with asafetida and method of use thereof |
| 02/15/2001 | WO2001010430A2 Use of estrogen compounds for prevention and treatment of ischemic damage |
| 02/15/2001 | WO2001010429A2 Long chain n-alkyl compounds and oxa-derivatives thereof and use as antiviral compositions |
| 02/15/2001 | WO2001010428A2 Use of n-methyl bases of ethanolamine for prevention of cell death induced by oxidative stress |
| 02/15/2001 | WO2001010427A2 Use of anti-muscarinic agents for treating skin disorders |
| 02/15/2001 | WO2001010426A2 Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer |
| 02/15/2001 | WO2001010425A2 Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes |
| 02/15/2001 | WO2001010424A2 Reducing cholesterol oxides using n-3-pufa and vitamin e |
| 02/15/2001 | WO2001010423A2 Use of 5-ht3 receptor antagonists for the treatment of inflammations of the respiratory tract |
| 02/15/2001 | WO2001010422A2 Use of hepoxilins or hepoxilin analogs as antidiabetics, antiinframmatory agents |
| 02/15/2001 | WO2001010421A1 Drug releasing biodegradable fiber implant |
| 02/15/2001 | WO2001010420A1 Transdermal patch comprising methylphenidate |
| 02/15/2001 | WO2001010413A2 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
| 02/15/2001 | WO2001010412A1 Epothilone compositions |
| 02/15/2001 | WO2001010411A2 Implantable active ingredient depot |
| 02/15/2001 | WO2001010410A1 Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof |
| 02/15/2001 | WO2001010409A1 Aqueous nasal formulation |
| 02/15/2001 | WO2001010408A2 Aqueous pharmaceutical composition containing moxifloxacin or salts thereof |
| 02/15/2001 | WO2001010407A1 Intravaginal clindamycin ovule composition |
| 02/15/2001 | WO2001010406A2 Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow |
| 02/15/2001 | WO2001010387A2 Antiviral therapy use of p-glycoprotein modulators |
| 02/15/2001 | WO2001010385A2 1,4-substituted 4,4-diaryl cyclohexanes |
| 02/15/2001 | WO2001010383A2 Caspase inhibitors and uses thereof |
| 02/15/2001 | WO2001010381A2 Methods for treating or preventing pain and anxiety |
| 02/15/2001 | WO2001010380A2 Benzanilides as potassium channel openers |
| 02/15/2001 | WO2001010378A2 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-$g(a)-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations |
| 02/15/2001 | WO2001010365A1 Patient temperature regulation method and apparatus |
| 02/15/2001 | WO2001010344A1 Nitric oxide releasing medical devices |
| 02/15/2001 | WO2001010323A1 Method of controlling body temperature while reducing shivering |
| 02/15/2001 | WO2001010199A1 A knockout mouse for the tumor suppressor gene anx7 |
| 02/15/2001 | WO2000078288A3 Novel process for paroxetine compositions |
| 02/15/2001 | WO2000068384A3 NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS |
| 02/15/2001 | WO2000066584B1 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV |
| 02/15/2001 | WO2000066109A3 Intravenous valproate for acute treatment of migraine headache |
| 02/15/2001 | WO2000065054A3 Human membrane-associated proteins |
| 02/15/2001 | WO2000064874A3 Heterosubstituted pyridine derivatives as pde 4 inhibitors |
| 02/15/2001 | WO2000062783A3 Ketolide antibacterials |
| 02/15/2001 | WO2000062740A3 Skin care compositions containing combination of skin care actives |
| 02/15/2001 | WO2000059920A3 Orally active 7.alpha.-alkyl androgens |
| 02/15/2001 | WO2000059513A8 NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1α, 25-DIHYDROXY VITAMIN D¿3? |
| 02/15/2001 | WO2000059490A3 Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions |
| 02/15/2001 | WO2000059483A3 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 02/15/2001 | WO2000058733A3 Assay for testing the efficacity of a therapy |
| 02/15/2001 | WO2000057920A3 Method for expressing proteins |
| 02/15/2001 | WO2000057900A3 Factor for regulation of neurite growth |